Cancer Drug Labels Often Do Not List Data On Survival After Treatment, Study Finds
Many newly approved cancer drugs fail to clearly communicate survival benefits associated with their use on the label, according to an analysis published Monday by JAMA Internal Medicine. Of the 125 drugs designed to treat cancer approved by the U.S. Food and Drug Administration between 2014 and 2018, 22 included evidence on their effects on overall survival on their package insert — the detailed information on effectiveness, safety and side effects provided — the data showed.